Atorvastatin Has Benefit as Secondary Prevention Against Recurrent Stroke
Atorvastatin treatment reduces the risk of stroke recurrence and mortality in patients who experienced a recent first stroke, according to a study presented here at the 14th Congress of the European Federation of Neurological Societies (EFNS).
Antoni Sicras-Mainar, MD, Badalona Serveis Assistencials (BSA), Badalona, Spain, reported the results on September 27 of a trial that aimed to determine whether atorvastatin has secondary preventive benefit in recent stroke patients.
This retrospective study evaluated a Mediterranean population without known coronary heart disease. The cohort consisted of consecutive patients with a first-ever acute stroke episode who were covered by the BSA health plan between January 2003 and December 2008 and had information regarding history of statin treatment, death, and hospitalisations due to stroke available throughout a 6-year follow-up. The study comprised 511 consecutive recent stroke patients, 20% of whom were treated with atorvastatin (65% received >20 mg/day).
National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.